Prostate genetic score (PGS‐33) is independently associated with risk of prostate cancer in the PLCO trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|75|12|1322-1328

ISSN： 0270-4137

Source： THE PROSTATE, Vol.75, Iss.12, 2015-07, pp. : 1322-1328

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prediction of individual genetic risk to prostate cancer using a polygenic score

By  

THE PROSTATE, Vol. 75, Iss. 13, 2015-09 ,pp. : 1467-1474

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial

By  

THE PROSTATE, Vol. 75, Iss. 11, 2015-08 ,pp. : 1160-1166

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 3, 2015-01 ,pp. : 206-211

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic risk of prostate cancer in Ugandan men

By  

THE PROSTATE, Vol. 78, Iss. 5, 2018-04 ,pp. : 370-376

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum Total Testosterone Is a Significant Preoperative Variable Independently Contributing to Separating the Prostate Cancer Population into Prostatectomy Gleason Score Groups

By  

Urologia Internationalis, Vol. 91, Iss. 1, 2013-06 ,pp. : 55-61

Karger

Access to resources Recommend Favorite